Presentation is loading. Please wait.

Presentation is loading. Please wait.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Published byΠλάτων Τρικούπη Modified over 5 years ago

Similar presentations

Presentation on theme: "Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with."— Presentation transcript:

1 Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with ST-segment elevation or non-ST-segment elevation myocardial infarction, who were alive at 2 years and had follow-up data. Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with ST-segment elevation or non-ST-segment elevation myocardial infarction, who were alive at 2 years and had follow-up data. (A) *6595 patients followed up and alive at 6 months. †1786 patients followed up and alive at 2 years. (B) *5170 patients followed up and alive at 6 months. †1387 patients followed up and alive at 2 years. ACS, acute coronary syndrome; AP, antiplatelet; ARB, angiotensin receptor blocker. Clara K Chow et al. Heart Asia 2019;11:e011122 Copyright © Asia Pacific Heart Association, British Cardiovascular Society & BMJ Publishing Group Ltd. All rights reserved.

Download ppt "Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with."

Similar presentations

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Volume 84, Issue 2, Pages (August 2013)

Volume 84, Issue 2, Pages (August 2013)
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.
Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.
Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.

Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.
Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).
In this example, optical coherence tomography was performed to examine tissue coverage of a stent implanted 3 weeks prior to the left circumflex artery.

In this example, optical coherence tomography was performed to examine tissue coverage of a stent implanted 3 weeks prior to the left circumflex artery.
Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.

Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.
Trends in relative risk of death before a mortality alert and after postalert 9-month lag period for (A) all diagnosis/procedure groups (for values 

Trends in relative risk of death before a mortality alert and after postalert 9-month lag period for (A) all diagnosis/procedure groups (for values 
Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)
Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.
Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.
Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.
Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.

Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.
Angiographic and corresponding optical coherence tomography (OCT) images. Angiographic and corresponding optical coherence tomography (OCT) images. (A)

Angiographic and corresponding optical coherence tomography (OCT) images. Angiographic and corresponding optical coherence tomography (OCT) images. (A)
Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.
Summary of literature search results

Summary of literature search results

Similar presentations

Ads by Google